retatrutide trial Weight Loss Results:Trial Data and FDA Status Trial of next-gen weight-loss drug

Retatrutide is the first triple-agonist GLP-1/GIP/Glucagon medication in Phase 3 trials, made by Eli Lilly

Retatrutide-specific long-term data is still being collected, but the biological mechanisms are identical

They also slow gastric emptying (the speed at which food moves from the stomach into the small intestine), helping stabilize blood sugar and further maintaining feelings of fullness

Want waar veel mensen spreken over afslankmedicatie alsof het een snelle oplossing is, zien we in de praktijk iets heel anders: GLP-1 medicijnen halen vooral de strijd in je hoofd weg , en maken daardoor ruimte voor echte gedragsverandering